The potential utility of PFKFB3 as a therapeutic target

被引:69
|
作者
Bartrons, Ramon [1 ]
Rodriguez-Garcia, Ana [1 ]
Simon-Molas, Helga [1 ]
Castano, Esther [1 ]
Manzano, Anna [1 ]
Navarro-Sabate, Aurea [1 ]
机构
[1] Univ Barcelona, Dept Ciencies Fisiol, Unitat Bioquim, IDIBELL, Catalunya, Spain
关键词
Cancer; glycolysis; metabolism; PFKFB3; inhibitors; N-BROMOACETYLETHANOLAMINE PHOSPHATE; BREAST-CANCER CELLS; 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE GENE PFKFB3; APOPTOSIS REGULATOR TIGAR; ACTIVATED PROTEIN-KINASE; FRUCTOSE 2,6-BISPHOSPHATE; INDUCIBLE; 6-PHOSPHOFRUCTO-2-KINASE; GLUCOSE-METABOLISM; RHEUMATOID-ARTHRITIS; BIFUNCTIONAL ENZYME;
D O I
10.1080/14728222.2018.1498082
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: It has been known for over half a century that tumors exhibit an increased demand for nutrients to fuel their rapid proliferation. Interest in targeting cancer metabolism to treat the disease has been renewed in recent years with the discovery that many cancer-related pathways have a profound effect on metabolism. Considering the recent increase in our understanding of cancer metabolism and the enzymes and pathways involved, the question arises as to whether metabolism is cancer's Achilles heel.Areas covered: This review summarizes the role of 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in glycolysis, cell proliferation, and tumor growth, discussing PFKFB3 gene and isoenzyme regulation and the changes that occur in cancer and inflammatory diseases. Pharmacological options currently available for selective PFKFB3 inhibition are also reviewed.Expert opinion: PFKFB3 plays an important role in sustaining the development and progression of cancer and might represent an attractive target for therapeutic strategies. Nevertheless, clinical trials are needed to follow up on the promising results from preclinical studies with PFKFB3 inhibitors. Combination therapies with PFKFB3 inhibitors, chemotherapeutic drugs, or radiotherapy might improve the efficacy of cancer treatments targeting PFKFB3.
引用
收藏
页码:659 / 674
页数:16
相关论文
共 50 条
  • [31] Functional diversity of PFKFB3 splice variants in glioblastomas
    Heydasch, Ulli
    Kessler, Renate
    Warnke, Jan-Peter
    Eschrich, Klaus
    Scholz, Nicole
    Bigl, Marina
    [J]. PLOS ONE, 2021, 16 (07):
  • [32] Structure-Based Development of Small Molecule PFKFB3 Inhibitors: A Framework for Potential Cancer Therapeutic Agents Targeting the Warburg Effect
    Seo, Minsuh
    Kim, Jeong-Do
    Neau, David
    Sehgal, Inder
    Lee, Yong-Hwan
    [J]. PLOS ONE, 2011, 6 (09):
  • [33] PFKFB3 is a p63 target gene that is required for proliferation, and inhibits differentiation in epidermal keratinocytes
    Hamanaka, R. B.
    Mutlu, G. M.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S80 - S80
  • [34] PFKFB3 promotes proliferation, migration and angiogenesis in nasopharyngeal carcinoma
    Gu, Miao
    Li, Li
    Zhang, Zhenxin
    Chen, Jing
    Zhang, Wei
    Zhang, Jie
    Han, Liang
    Tang, Mingming
    You, Bo
    Zhang, Qicheng
    You, Yiwen
    [J]. JOURNAL OF CANCER, 2017, 8 (18): : 3887 - 3896
  • [35] Inhibition of PFKFB3/glycolysis overcomes chemoresistance in ovarian cancers
    Mondal, Susmita
    Roy, Debarshi
    Kalogera, Eleftheria
    Khurana, Ashwani
    Tapolsky, Gilles H.
    Telang, Sucheta
    Chesney, Jason
    Shridhar, Viji
    [J]. CANCER RESEARCH, 2015, 75
  • [36] Tumor vessel disintegration by maximum tolerable PFKFB3 blockade
    Lena-Christin Conradi
    Aleksandra Brajic
    Anna Rita Cantelmo
    Ann Bouché
    Joanna Kalucka
    Andreas Pircher
    Ulrike Brüning
    Laure-Anne Teuwen
    Stefan Vinckier
    Bart Ghesquière
    Mieke Dewerchin
    Peter Carmeliet
    [J]. Angiogenesis, 2017, 20 : 599 - 613
  • [37] PFKFB3 regulation by p38 MAPK pathway
    Novellasdemunt Vilaseca, L.
    Cuesta, A. M.
    Ventura, F.
    Rosa, J. L.
    Rider, M. H.
    Sabate, A. N.
    Bach, R. B.
    [J]. FEBS JOURNAL, 2012, 279 : 271 - 271
  • [38] A high-throughput screening campaign against PFKFB3 identified potential inhibitors with novel scaffolds
    Jie Li
    Yan Zhou
    Guy Eelen
    Qing-tong Zhou
    Wen-bo Feng
    Viktorija Labroska
    Fen-fen Ma
    Hui-ping Lu
    Mieke Dewerchin
    Peter Carmeliet
    Ming-wei Wang
    De-hua Yang
    [J]. Acta Pharmacologica Sinica, 2023, 44 : 680 - 692
  • [39] PFKFB3 regulates lipopolysaccharide-induced excessive inflammation and cellular dysfunction in HTR-8/Svneo cells: Implications for the role of PFKFB3 in preeclampsia
    Zhang, Yang
    Liu, Weifang
    Wu, Mengying
    Li, Qi
    Liu, Yu
    Yang, Liu
    Chen, Yangyang
    Zhong, Yanqi
    Liu, Xiaoxia
    Zou, Li
    [J]. PLACENTA, 2021, 106 : 67 - 78
  • [40] Tumor vessel disintegration by maximum tolerable PFKFB3 blockade
    Conradi, Lena-Christin
    Brajic, Aleksandra
    Cantelmo, Anna Rita
    Bouche, Ann
    Kalucka, Joanna
    Pircher, Andreas
    Bruning, Ulrike
    Teuwen, Laure-Anne
    Vinckier, Stefan
    Ghesquiere, Bart
    Dewerchin, Mieke
    Carmeliet, Peter
    [J]. ANGIOGENESIS, 2017, 20 (04) : 599 - 613